Search

Crimean–Congo hemorrhagic fever virus (CCHFV) is a highly pathogenic bunyavirus with a fatality rate of up to 40%. Currently, there are no licensed antiviral drugs for the treatment of CCHF; thus, the World Health Organization (WHO) listed the disease as a priority. A unique viral transcription initiation mechanism called "cap-snatching" is shared by influenza viruses and bunyaviruses. Thus, we tested whether baloxavir (an FDA-approved anti-influenza drug that targets the "cap-snatching" mechanism) could inhibit CCHFV infection. In cell culture, baloxavir acid effectively inhibited CCHFV infection and targeted CCHFV RNA transcription/replication. However, it has weak oral bioavailability. Baloxavir marboxil (the oral prodrug of baloxavir) failed to protect mice against a lethal dose challenge of CCHFV. To solve this problem, baloxavir sodium was synthesized owing to its enhanced aqueous solubility and pharmacokinetic properties. It consistently and significantly improved survival rates and decreased tissue viral loads. This study identified baloxavir sodium as a novel scaffold structure and mechanism of anti-CCHF compound, providing a promising new strategy for clinical treatment of CCHF after further optimization. [Display omitted] • Baloxavir acid effectively inhibits Crimean–Congo hemorrhagic fever virus (CCHFV) infection in vitro. • Baloxavir acid inhibits CCHFV infection during viral transcription and replication. • Baloxavir marboxil failed to protect mice from lethal CCHFV infection after oral administration. • Baloxavir sodium with enhanced pharmacokinetic properties significantly improves the survival rate of CCHFV-infected mice. [ABSTRACT FROM AUTHOR]